Back

Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.

Canvuparatide

PipelinePhase 3PeptideInvestigational

Sponsor:: MBX Biosciences
Active US trials:: 1
Earliest primary completion:: Jan 1, 2028

👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

Synopsis

Generated with AlphaAI

Product:

Canvuparatide

Category:

Indication:

Mechanism:

Safety:

Dosing:

Patient:

Reviews:

No reviews yet

Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (1)

NCT	Phase	Status	Sponsor	Primary Completion
NCT07699471	Phase 3	RECRUITING	MBX Biosciences	Jan 1, 2028

About this drug

Status

Active in clinical trials

Last Refreshed

Nov 13, 2026

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Canvuparatide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers